Page last updated: 2024-10-21

3-methoxytyramine and Parkinsonian Disorders

3-methoxytyramine has been researched along with Parkinsonian Disorders in 8 studies

3-methoxytyramine: RN given refers to parent cpd
3-methoxytyramine : A monomethoxybenzene that is dopamine in which the hydroxy group at position 3 is replaced by a methoxy group. It is a metabolite of the neurotransmitter dopamine and considered a potential biomarker of pheochromocytomas and paragangliomas.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
" In this study, we aimed to investigate the effects of neuroprotective compounds, TIQ and 1MeTIQ, on the dopamine release in vivo in an animal model of PD induced by chronic administration of 1BnTIQ (25 mg/kg i."1.43Comparison of the Effects of Acute and Chronic Administration of Tetrahydroisoquinoline Amines on the In Vivo Dopamine Release: A Microdialysis Study in the Rat Striatum. ( Antkiewicz-Michaluk, L; Romańska, I; Wąsik, A, 2016)
"Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)."1.42Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015)
" Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i."1.40Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates. ( Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C, 2014)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's5 (62.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gruden, MA1
Davydova, TV1
Narkevich, VB1
Fomina, VG1
Wang, C1
Kudrin, VS1
Morozova-Roche, LA1
Sewell, RD1
Oeckl, P1
Scheffold, A1
Lechel, A1
Rudolph, KL1
Ferger, B1
Morin, N1
Morissette, M2
Grégoire, L1
Di Paolo, T2
Konieczny, J1
Czarnecka, A1
Kamińska, K1
Lenda, T1
Nowak, P1
Wąsik, A1
Romańska, I1
Antkiewicz-Michaluk, L1
Viaggi, C1
Vaglini, F1
Pardini, C1
Caramelli, A1
Corsini, GU1
Abe, K1
Taguchi, K1
Wasai, T1
Ren, J1
Utsunomiya, I1
Shinohara, T1
Miyatake, T1
Sano, T1

Other Studies

8 other studies available for 3-methoxytyramine and Parkinsonian Disorders

ArticleYear
Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
    Behavioural brain research, 2014, Apr-15, Volume: 263

    Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; alpha-Synuclein; Amyloid; Animals; Corpu

2014
Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion.
    Neuroreport, 2014, Mar-26, Volume: 25, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat

2014
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Progress in neuro-psychopharmacology & biological psychiatry, 2015, Jan-02, Volume: 56

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide;

2015
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
    Behavioural brain research, 2015, Apr-15, Volume: 283

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose

2015
Comparison of the Effects of Acute and Chronic Administration of Tetrahydroisoquinoline Amines on the In Vivo Dopamine Release: A Microdialysis Study in the Rat Striatum.
    Neurotoxicity research, 2016, Volume: 30, Issue:4

    Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Male; Microdialysis; Motor Activity; Neuroprote

2016
Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys.
    Journal of neuroscience research, 2009, May-15, Volume: 87, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Biogenic Amines; Chromatogra

2009
MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
    Neuropharmacology, 2009, Volume: 56, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum;

2009
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
    Brain research bulletin, 2001, Sep-01, Volume: 56, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Do

2001